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Abstract   
Introduction: Toxoplasma gondii (T. gondii) is distributed worldwide and infects most 
species. The serious incidence and severe or fatal injury caused by T. gondii infection clearly 
indicates the necessity for the event of a vaccine. The current study goals were to evaluate 
serological applications of Toxoplasma gondiirhoptry protein 1 (ROP1) antigen. 
Materials and methods: We created a polymer vaccine by using the eukaryotic plasmid, 
pROP1. Purification by one-step metal affinity chromatography allowed recovery of milligram 
amounts of purified recombinant proteins per liter of culture. The quality of 
this matter for diagnosing of human infections was provided and tested on 77 serum samples 
which were obtained during routine diagnostic tests. A panel of 20 serum samples from patients 
with acute toxoplasmosis was compared to a panel of 35 serum samples from individuals with 
chronic toxoplasmosis. 
Results: Results of the study indicated that antibodies detected from patients with acute and 
chronic infections were 96% and 17%, respectively, by using of pROP1 recombinant antigen. 
Conclusion: According to the present study an immunoglobulin G antibody against ROP1 
antigen is made throughout the acute stage of toxoplasmosis infection, but not in the chronic 
phase of toxoplasmosis. 
Keywords: Toxoplasma gondii, ROP1, Recombinant antigen, Acute toxoplasmosis
Introduction  
Toxoplasma gondii (T. gondii) is a parasite 
belonging to the Apicomplexa (1, 2). This 
parasite is distributed across worldwide and 
infects most species of animals and 
humans. Toxoplasmosis is immune 
competent in adults and is usually 
asymptomatic. 
 Toxoplasmosis is a main cause of fatality 
in congenitally infected patients and 
immune compromised patients (3-5). The 
live vaccine is dangerous because of the 
reversing to pathogenic phenotype and low 
shelf life. Additionally, DNA vaccines can 
exert potent, long-lasting humeral and cell-
mediated immunity (6, 7). T. gondii 
infections usually promote to activate CD4+ 
and CD8+ T cells, simultaneously (7, 8). 
Like others unicellular organisms T. gondii 
is composed of various antigens. Somatic 
and excreted/secreted antigens are the most 
important Toxoplasma antigens that the 
secreted ones can activate potent immune 
response (9, 10). In the present study, we 
constructed a plasmid expressing the ROP1 
antigen (pROP1), then examined their 
expression in eukaryotic cells and evaluated 
the usefulness of the T. gondii recombinant 
r-ROP1 antigen for diagnostic purposes. 
The antigenicity of recombinant antigen 
against human serum samples was 
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evaluated by Western blotting and ELISA 
analysis. 
 
Material and methods 
Animals and T. gondii strains: Some old 
female BALB/c mice were purchased and 
kept under sterile in animal laboratory of 
theSanandaj Azad University. A highly 
virulent strain of T. gondii preserve (RH 
strain) in BALB/c mice was used for 
production of tachyzoites. 
DNA extraction and polymerase chain 
reaction: About 5 ×107 tachyzoites (100μl) 
were concentrated by centrifugation and 
washed with phosphate buffer saline and 
then lysed in 900μl lysis buffer and then 
treated with 10 μl proteinase K (100μg/ml) 
at 55°C for 2 h. The proteins were removed 
by adding an equal volume of 
phenol/chloroform to lysate. The lysate 
tube was centrifuged (13000 RPM /15 min) 
and an equivalent volume of chloroform 
was added to the supernatant. DNA pellet 
was obtained after adding equal content of 
100% ethanol and 1/10 volume of 3M 
sodium acetate to this supernatant and 
centrifugation at 13000 RPM for 10 min 
and then washing with 70% ethanol. The 
DNA pellet dissolved in sterile distilled 
water and stored at -20°C until use. 
Extracted DNA products were examined on 
0.8% agarose gel. The sequence provided 
by digestion of BglII and HindIIIwas 
designed for cloning. From the GenBank 
database (http://www.ncbi.com) we took 
the sequences of the gene encoding ROP1 
antigen of T. gondii (accession no.  
M71274). 
The forward (F) and reverse (R) sequences 
of primers were appropriately determined 
as follow: 
F: GTGCCAGATCTAGCGTCGCATTCTCATTCG 
R: CCAAAGCTTTTGCGATCCATCATCCTGCTCTG 
The DNA segment of rop1 (corresponding 
to nucleotides 252 to 1188) encodingROP1 
was obtained by PCR using above primer. 
DNA extracted from tachyzoites was used 
as a template to amplify the ROP1 gene by 
PCR performed in 25μl of solution 
containing 3μl of template DNA, 0.5μl 
TaqDNA polymerase, 2.5μl 10X PCR 
buffer, 0.75μl  MgCl2, 15.75μl distilled 
water and 1μl each of primers under the 
following conditions: After an early 5 min 
denaturation at 94°C, each cycle consisted 
of 60s at 94°C, 30s at 62°C and 60sat 72°C 
at the end of the 32 cycles of amplification 
and 30 min at 72°C was final extension. The 
PCR products checked out by 
electrophoresis on a 1% agarose gel and 
taken a photo. The molecular weight 
markers used were the 1kbp DNA ladders 
(Fermentas). 
Cloning of ROP1: The pUET1 cloning 
vector was used and ligation was done 
according to our previous study (11). The 
ligation product used to transform and was 
accomplished Escherichia coli BL21 plus. 
Competent cell was prepared and the 
ligation output was a shiftin competent cell. 
According to protocol(12) retrieved in 
Luria-Bertani (LB) broth and LB broth 
medium free antibiotic by incubating at 37 
ºC for 2 hours and then were plated onto LB 
agar plates contained IPTG 200 mg /ml, 
ampicillin 100 mg/ml and X-Gal 20 mg/ml, 
and plates were incubated at 37ºC for 
overnight to screening white and blue 
colonies. The selected colony of both color 
passages in LB broth or LB agar incubated 
at 37 ºC for an overnight. Based on the 
protocol, DNA plasmid was extracted and 
the cloned ROP1 was verified by PCR, 
nucleotide sequencing and restriction 
digestion. 
Sub-cloning of the pT-ROP1 
inpcDNA3eukaryote expression vector: 
The digested pT-ROP1by EcoR1 and 
HindIII inserted into the digested pcDNA3 
vector and the inserted product was 
transformed into CHO cells (competent 
cells). The plasmid was extracted and 
identify by electrophoresis, PCR 
amplification and restriction digestion (11). 
SDS-PAGE and Western blot analysis: 
After 48h, pellets of transfected cells were 
suspended in 150ml SDS-PAGE sample 
buffer and then sonicated and heated 
(100°C/ 5 min). Lysates were separated on 
a 12%polyacrylamide gel, transferred to 
D
ow
nl
oa
de
d 
fro
m
 jb
rm
s.m
ed
ila
m.
ac
.ir 
at 
9:4
7 I
RS
T o
n T
ue
sd
ay
 D
ec
em
be
r 5
th 
20
17
Original article                                                               J Bas Res Med Sci 2017; 4(3):39-41. 
41 
 
poly vinyl idenedifluoridecoats, and then 
blocked with Tris-buffered saline (20mM 
Tris, 137mM NaCl, pH 7.6) containing 
0.1% Tween 20 and 5% skim milk. 
Membranes were washed with buffer and 
then for 2hours at room temperature mixed 
with primary antibody of mouse anti-
FLAG. Interested antibody was washed out 
with TBST. Peroxidase activity was a study 
using enhanced chemoluminesce (ECL) 
Western blotting detection system. 
ELISA assay: MaxiSorp multi well plates 
were coated with 0.1 ml of r-ROP1 protein 
at a final concentration of 1 g/ml for antigen 
in a coating buffer (0.05M carbonate buffer, 
pH 9.6). Control plates were incubated at 
4°C with the extract recombinant proteins 
as mentioned above. After overnight, 
controls were washed (PBS–0.1% Triton 
X-100) and blocked (37°C for 1 hour) by 
using blocking solution (1% bovine serum 
albumin–1% Triton X-100–PBS). 
Afterward, they were covered (1hour at 
37°C) with human serum specimens diluted 
1:100 in the blocking solution. Plates were 
washed with PBS–0.1%, Triton X-100 and 
added to each well from the conjugates of 
anti-human IgG peroxidase-labeled (1 
mg/ml), diluted 1: 4,000 in blocking 
solutions. Next, the plates were 
incubated35 min at 37°C and then washed. 
Finally, by incubating the plates with o-
phenylene diamine dihydrochloride 
chromogenic substrate was revealed 
enzymatic activity. After 40min at 37°C in 
darkness, by adding 0.1 ml of 1 M sulfuric 
acid was stopped the color development 
reaction and the color intensity was 
measured using a Microtiter plate reader at 
490 nm. Each serum sample was examined 
and calculated of the optical density (OD) 
reading. 
Serum samples: A total of 77 healthy 
human serum samples was analyzed and 
based on serological profiles divided into 
three classes. The class I consisted of 20 
human serum specimens from patients in 
the acute phase of toxoplasmosis. The 
presences of specific IgM, antibodies were 
measured by IgM-ELISA Vistas'. All serum 
samples had positive IgG antibodies. Class 
II consisted of 35 human serum samples 
from patients with chronic toxoplasmosis. 
By an absence of specific IgM antibodies 
and an antibody avidity test evaluated all 
those serum samples had positive IgG 
antibodies high avidity. Class III (the 
control group) included 22 human serum 
samples from serious negative individuals. 
For more, statistical analysis of the ELISA 
results was evaluated with the Microsoft 
Excel schedule for assessment of the 2 test. 
Results 
The sequence analysis verified that PCR-
created change and the resulting vector 
included of 1686 base pairs (accordance 
with Gene Bank, Z36906.1) from ROP1 
gene. ROP1 indicated in vitro by 
transfected CHO cells (competent cells) 
ROP1 was synthesized during 
an organism system (Figures 1, 2 and 3). 
 
Figure1. Figure shows the result of electrophoresis 
pUET1 and pT-ROP1 plasmids. Lane 1: Plasmid 
extracted from pT-ROP1 and Lane 2: Plasmid 
extracted from pUET1.  
The CHO cells (transfected and non-
transfected control cells) were produced for 
48h following the transaction and list in 
sample buffer. The ROP1 antigen described 
in detail as soluble protein with calculated 
molecular weight 39 kDa. The immune 
action of the purified antigen r-ROP1 was 
tested by Western blot analysis with 4 
human serum samples selected from each 
of the three serum sample groups that we 
were assayed (Figure 4). IgG antibodies 
present in serum group I samples in the 
serious stage of toxoplasmosis efficiently 
identified the r-ROP1 antigen. In contrast, 
D
ow
nl
oa
de
d 
fro
m
 jb
rm
s.m
ed
ila
m.
ac
.ir 
at 
9:4
7 I
RS
T o
n T
ue
sd
ay
 D
ec
em
be
r 5
th 
20
17
Original article                                                               J Bas Res Med Sci 2017; 4(3):39-41. 
42 
 
IgGs from patients group II in the 
continuous stage of infection reacted 
weakly with Rop1. Moreover, 
immunoreactions of r-ROP1 antigen with 
serum samples from healthy patients (group 
III) was not studied.
  
 
 
Figure 2. Digestion of extracted pT-ROP1 after RANs formation. Lane1: ladder 1kb, Lanes 2: (ROP1 757bp, 
pUET12876 bp). 
 
 
 
Figure 3. Detection of pcDNA3-ROP1 by enzyme Digestion. Lane1: ladder 1kb, 2: pcROP1, 3: pc-ROP1 after 
digestion EcoRI enzyme, 4: pc-ROP1 after digestion with HindIII and 5: pcROP1 after digestion with each other 
enzymes (ROP1˜ 760 bp). 
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Figure 4. Expression of Recombinant ROP1 Protein in SDS-PAGE gel. L: protein size marker; Lane 1: p-ROP1 
before induction without expected protein, Lane 2 and 3: p-ROP1 after induction that expressed expected protein. 
Discussion 
Chen et al. cloned a 750bp fragment of        
T. gondii ROP1 sequence into 
PUC18 cellular inclusion so transferred it 
to pcDNA3 organism expression cellular 
inclusion (12).  
Another group constructed a fusion-based 
recombinant plasmid (pSAG1-ROP1).By 
liposome-entrapped particles Recombinant 
plasmids were injected into Balb/c mice 
and immune responses were analyzed 
(13).The recombinant antigenic proteins are 
encouraging tools that can be used in 
diagnostic tests for the between serious and 
constant infections. Aubert et al. 
producedROP1 in fusion with cks protein 
of E.coli and to identify specific IgM and 
IgG antibodies of toxoplasmosis in human 
serum used these recombinant antigens 
(14).The fragments of ROP1 and SAG1 
genes into pRP261 expression vector 
cloned and used the resulting explicit 
proteins to serological assessment of 
toxoplasmosis in patients suffering from 
acute and chronic toxoplasmosis by Meek 
et al. (15). 
In this research reported the bacterial 
production of T. gondii soluble r-ROP1 
antigen protein by the use of the effective 
expression system developed in our 
laboratory (11).This expression system and 
the method of disinfection by a one-step 
metal attraction chromatography led to the 
production of14 mg of r-ROP1 per liter of 
culture(11). In this work, we appraised the 
diagnostic avail and worthiness of T.gondii 
recombinant antigenic protein r-ROP1 and 
then tested r-ROP1 restarts by the use of 
two separate classes of human serum 
parable show serious and constant 
infections. Both groups were analyzed by 
ELISA techniques and Western blot. IgG 
antibodies in serum samples from patients 
in the serious stage of toxoplasmosis(group 
I; serum samples with positive IgM and IgG 
at low enthusiasm) respond with the 
recombinant antigens more potent than 
those in serum specimens from patients in 
the constant state of toxoplasmosis(group 
II; serum samples with positive IgG at high 
acting and  negative IgM. Thus, our results 
with r-ROP1 antigen imply that these 
recombinants can be used as serological 
indicator of recently obtained infection. 
The r-ROP1 antigen was shown before to 
be sensitive in its capability to discover IgG 
antibodies in serum samples from patients 
with toxoplasmosis (12-15). The usefulness 
of this antigen for diagnosis of human 
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infections was provided and tested on 77 
serum samples which are obtained during 
routine diagnostic tests. A panel of 20 
serum samples from patients with acute 
toxoplasmosis was compared to a panel of 
35 serum samples from individuals with 
chronic toxoplasmosis. The results 
indicated that ROP1 recombinant antigen 
detected antibodies further in individuals 
with acute infections (96%) than in 
individuals with chronic infections (17%). 
The results of this study show that special 
IgG anti-ROP1 antibodies are present in 
serum samples from patients at the serious 
stage of T. gondii infection. Successful use 
of recombinant antigenic proteins for the 
finding of anti-T. gondii- special antibodies 
has been reported by a number of authors 
(15-16). 
Conclusion 
These data imply thatROP1 antigen is 
specifically encouraging candidates for 
efficient vaccine against toxoplasmosis. 
Additionally, results suggest that an 
immunoglobulin G antibody against ROP1 
antigen is created during the acute stage of 
infections but not generally in the persistent 
phase of the sickness.  
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